Veru (NASDAQ:VERU) PT Raised to $3.00 at HC Wainwright

Veru (NASDAQ:VERU) had its price target boosted by analysts at HC Wainwright from $2.00 to $3.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 84.05% from the stock’s previous close.

VERU has been the subject of several other reports. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 target price (down from $7.00) on shares of Veru in a research report on Monday, April 15th. Raymond James initiated coverage on shares of Veru in a report on Thursday, March 28th. They set an “outperform” rating and a $3.00 target price on the stock.

Veru Stock Performance

Veru stock opened at $1.63 on Monday. The company’s 50 day simple moving average is $0.98 and its 200-day simple moving average is $0.81. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The company has a market capitalization of $238.60 million, a price-to-earnings ratio of -2.17 and a beta of -0.47.

Veru (NASDAQ:VERU) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.09) EPS for the quarter. Veru had a negative return on equity of 257.92% and a negative net margin of 405.04%. The firm had revenue of $2.14 million for the quarter. Equities analysts expect that Veru will post -0.26 earnings per share for the current year.

Institutional Investors Weigh In On Veru

A number of large investors have recently modified their holdings of VERU. Choreo LLC purchased a new stake in shares of Veru during the 1st quarter worth $64,000. Rosalind Advisors Inc. lifted its holdings in Veru by 12.5% during the 1st quarter. Rosalind Advisors Inc. now owns 4,500,000 shares of the company’s stock worth $3,150,000 after buying an additional 500,000 shares during the last quarter. 180 Wealth Advisors LLC acquired a new position in shares of Veru during the 1st quarter worth about $120,000. Perceptive Advisors LLC increased its holdings in shares of Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock valued at $4,021,000 after acquiring an additional 4,494,821 shares during the last quarter. Finally, Octagon Capital Advisors LP acquired a new stake in shares of Veru during the 4th quarter worth about $2,736,000. 47.16% of the stock is owned by hedge funds and other institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.